Format

Send to

Choose Destination
See comment in PubMed Commons below
Asian J Transfus Sci. 2010 Jan;4(1):3-8. doi: 10.4103/0973-6247.59384.

Leukoreduced blood components: Advantages and strategies for its implementation in developing countries.

Author information

1
Department of Transfusion Medicine, PGIMER, Chandigarh, India.

Abstract

Removal of leucocytes from various blood products has been shown to minimize Febrile nonhemolytic transfusion reactions, HLA alloimmunization, platelet refractoriness in multitransfused patients and prevention of transmission of leukotropic viruses such as EBV and CMV. Rapidly growing size of hemato-oncological patients in our country requiring multiple transfusion of blood and components during the course of their management pose a great challenge to transfusion services to provide them red cell and platelet antigen matched products in alloimmunized subjects. Thus removal of leucocytes below a certain threshold, </= 5 x 10(6) in a blood component certainly helps in prevention of alloimmunization and associated risks in these patients. Currently the best Leucoreduction can be achieved with the help of 3rd and 4th generation leukofilters, both in laboratory and patient bed side, and state of the art apheresis devices. The present article briefly reviews the current literature for pros and cons of leucofilteration and its scope of implementation in the cost constrained settings.

KEYWORDS:

Blood component; developing countries; leukoreduced component

PMID:
20376259
PMCID:
PMC2847337
DOI:
10.4103/0973-6247.59384
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Medknow Publications and Media Pvt Ltd Icon for PubMed Central
    Loading ...
    Support Center